‘Providing a specific platform for the clinical trials community in the DACH region to develop innovative clinical operations and outsourcing strategies’
After a hugely successful 2023 conference, we are pleased to announce that the Outsourcing Clinical Trials DACH event will be returning to Munich. This event will focus upon the operational challenges in clinical development found within Germany, Austria and Switzerland. Over two days, delegates will discuss the common challenges and trends impacting the region, including steps for defining contractual relationships and getting the maximum from external providers, incentivising good relationships with CROs and constructing defined deadlines.
- Focused conference for the DACH pharma market– Unlike other conferences, our event specifically focuses on the local pharma industry in Switzerland, Germany and Austria, highlighting the current challenges and exciting innovations and opportunities within the market
- Excellent speaker line up – Senior level speakers from leading organisations such as Roche, AstraZeneca and Novartis along with exciting biotechs like Medac and Medigene
- Great and Diverse Sessions – Our OCT DACH covers a variety of topics ranging from updated EMA Guidance to Direct to Patient and Data management innovation to CRO relationship
- Unbeatable Networking Opportunities – Meet and network with over 150 senior industry decision makers during our dedicated networking breaks, round tables and interactive sessions
WHAT TO EXPECT FOR 2024?
Join pharma and biotech experts to discuss new trends and opportunities and learn how they optimize their clinical operations enabling you to stay ahead of the game. Find the right solution providers to partner with, allowing you to accelerate your trial timelines.
It was very interesting, both the presentations and the meeting opportunities.
A great networking opportunity.
We had 2.5 great days in Zurich and made a bunch of really interesting contacts. Even more important: Our brand was visible to so many decision-makers that we expect to help quit a bit in the long run.
Excellent Agenda, Overall nice experience for me